Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

Ferrannini, Ele, Muscelli, Elza, Frascerra, Silvia, Baldi, Simona, Mari, Andrea, Heise, Tim, Broedl, Uli C., Woerle, Hans-Juergen·2014·Journal of Clinical Investigation

DOI 10.1172/jci72227

Cited by (999)

Items 601–700 of 999

SGLT2 inhibition and ketoacidosis – should we be concerned?
Surya Panicker Rajeev, John P.H. Wilding · 2015 · The British Journal of Diabetes
Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations
Ordelheide, Anna-Maria, Böhm, Anja, Kempe-Teufel, Daniela, Wagner, Robert, Machicao, Fausto, Heni, Martin, Stefan, Norbert, Fritsche, Andreas, Häring, Hans-Ulrich, Staiger, Harald · 2017 · PLOS ONE
Macrophages: friend or foe in diabetes pathogenesis and therapy
Rachel N. Grimes, Marco Orecchioni, Estefanía Quesada‐Masachs · 2025 · Frontiers in Immunology
Does Dapagliflozin Affect Energy Intake and Appetite? A Randomized, Controlled Exploratory Study in Healthy Subjects
Elizabeth A. Bertran, Helen D Berlie, Aaron Nixon, Linda A. Jaber · 2018 · Clinical Pharmacology in Drug Development
Synthesis of Chiral Tetrahydrofuran Building Blocks from Pantolactones: Application in the Synthesis of Empagliflozin and Amprenavir Analogs
Paresh R. Athawale, Neeta Kumari, Monica Dandawate, K. Kashinath, D. Srinivasa Reddy · 2019 · European Journal of Organic Chemistry
Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass
Antonio Ferreira, Katja A. Schönenberger, Natascha Potoczna, Andreas P. Vogt, Philipp A. Gerber, Jörg Zehetner, Daniel Giachino, Philipp Christoph Nett, Joanna Gawinecka, Luca Cossu et al. · 2023 · Diabetes Technology & Therapeutics
No evidence of compensatory changes in energy balance, despite reductions in body weight and liver fat, during dapagliflozin treatment in type 2 diabetes mellitus: A randomized, double‐blind, placebo‐controlled, cross‐over trial (ENERGIZE)
Surya Panicker Rajeev, Carl Alexander Roberts, Emily E. Brown, Victoria S. Sprung, Jo A. Harrold, Jason C. G. Halford, Andrej Stančák, Emma Jane Boyland, Graham John Kemp, Julie Perry et al. · 2023 · Diabetes Obesity and Metabolism
Empagliflozin improves vascular insulin sensitivity and muscle perfusion in persons with type 2 diabetes
Linda A. Jahn, Lee M. Hartline, Thi Thuy Dung Nguyen, Kevin W. Aylor, William B. Horton, Zhenqi Liu, Eugene J. Barrett · 2024 · American Journal of Physiology-Endocrinology and Metabolism
Proinsulin-producing, hyperglycemia-induced adipose tissue macrophages underlie insulin resistance in high fat-fed diabetic mice
Eric Dale Buras, Lina Yang, Pradip Saha, Jongoh Kim, Pooja Mehta, Yisheng Yang, Susan Galloway Hilsenbeck, Hideto Kojima, Wenhao Chen, C. Wayne Smith et al. · 2015 · The FASEB Journal
Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin
Ronnie Aronson · 2015 · Current Medical Research and Opinion
SGLT1 inhibition boon or bane for diabetes‐associated cardiomyopathy
Jaspreet Kalra, Sureshbabu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar · 2019 · Fundamental and Clinical Pharmacology
Comparison of mechanisms and transferability of outcomes of SGLT2 inhibition between type 1 and type 2 diabetes
Oliver Schnell, Paul Elie Valensi, Eberhard Standl, Antonio Ceriello · 2020 · Endocrinology Diabetes & Metabolism
Effectiveness and safety of sodium–glucose co-transporter-2 inhibitors in Thai adults with type 2 diabetes mellitus: a real-world study
Chutintorn Sriphrapradang, Yotsapon Thewjitcharoen, Supawan Buranapin, Kittisak Sawanyawisuth, Nalin Yenseung, Wisawa Ubonchareon, Laddawan Limpijankit, Thep Himathongkam · 2020 · Current Medical Research and Opinion
Cardiorenal Syndrome in Type 2 Diabetes Mellitus – Rational Use of Sodium–glucose Cotransporter-2 Inhibitors
Sanjay Kalra, Hasan Aydin, Manisha Sahay, Sujoy Kumar Ghosh, Sundeep Ruder, MANGESH HARIHAR TIWASKAR, Gary Kilov, Kamal Kishor, Tiny Nair, Vikas Makkar et al. · 2020 · touchREVIEWS in Endocrinology
Sodium-Glucose Cotransporter-2 Inhibitors in Vascular Biology: Cellular and Molecular Mechanisms
Lei Xiao, Xin Nie, Yanyan Cheng, Nanping Wang · 2021 · Cardiovascular Drugs and Therapy
Revisiting Regulators of Human β-cell Mass to Achieve β-cell–centric Approach Toward Type 2 Diabetes
Hironobu Sasaki, Yoshifumi Saisho, Jun Inaishi, Hiroshi Itoh · 2021 · Journal of the Endocrine Society
Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes
Věra Čertíková Chábová, Oskar Zakiyanov · 2022 · International Journal of Molecular Sciences
Stem Cells Therapy in Diabetes Mellitus
Xi Yang · 2014 · Journal of Stem Cell Research & Therapy
Different glucagon effects during DPP‐4 inhibition versus SGLT‐2 inhibition in metformin‐treated type 2 diabetes patients
Wathik Alsalim, Margaretha Persson, Bo Åhrén · 2018 · Diabetes Obesity and Metabolism
Sodium-glucose cotransporter-2 inhibitors induced eu-glycemic diabetic ketoacidosis: The first report in a type 2 diabetic (T2D) Taiwanese and literature review of possible pathophysiology and contributing factors
Yi-Hsin Lin · 2018 · Journal of the Formosan Medical Association
Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
A K Pancholia · 2018 · Indian Heart Journal
Mechanistic effects of SGLT2 inhibition on blood pressure in diabetes
Habib Yaribeygi, Stephen Lawrence Atkin, Amirhossein Sahebkar · 2019 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
Favourable effect of the sodium‐glucose co‐transporter‐2 inhibitor canagliflozin plus the dipeptidyl peptidase‐4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open‐label, prospective, randomized, parallel‐group comparison trial (the CALMER study)
Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama et al. · 2019 · Diabetes Obesity and Metabolism
Pathogenesis of Type 2 Diabetes Mellitus
Ralph Anthony DeFronzo · 2018 · Endocrinology
Observational Study on Unhealthy Eating Behavior and the Effect of Sodium-Glucose Cotransporter 2 Inhibitors: The Luseogliflozin Ehime Diabetes Study
Shinya Furukawa, Teruki Miyake, Hiroaki Miyaoka, Bunzo Matsuura, Yoichi Hiasa · 2022 · Diabetes Therapy
A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin
Aditi Jain, Abhay Vispute, Amol Dange, Arindam Naskar, Asish Mondal, B. Vivekanand, Balram Sharma, Deepak Varade, Dhaiwat Shukla, Girish Bhatia et al. · 2023 · Diabetes Therapy
Ketosis prevents abdominal aortic aneurysm rupture through C–C chemokine receptor type 2 downregulation and enhanced extracellular matrix balance
Sergio Sastriques-Dunlop, Santiago Elizondo-Benedetto, Batool Arif, Rodrigo Meade, Mohamed S. Zaghloul, Hannah P. Luehmann, Gyu Seong Heo, Sean J. English, Yongjian Liu, Mohamed Adel Zayed · 2024 · Scientific Reports
Autophagy-lysosome pathway in insulin & glucagon homeostasis
Yi Wu, Hui Wang, Hengyong Xu · 2025 · Frontiers in Endocrinology
Impact of SGLT2 Inhibitors on Cardiovascular Risk Scores, Metabolic Parameters, and Laboratory Profiles in Type 2 Diabetes
Nazif Yalçın, Selman Aktaş, Seyit Uyar, Nizameddin Koca · 2025 · Life
Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?
Ronald Goldenberg, Subodh Verma, Bruce A. Perkins, Jeremy D. Gilbert, Bernard Zinman · 2016 · Canadian Journal of Diabetes
The Role of Sodium Glucose Cotransporter-2 Inhibitors in Atherosclerotic Cardiovascular Disease: A Narrative Review of Potential Mechanisms
Jennifer Barraclough, Sanjay Patel, Jie Yu, Bruce Charles Neal, Clare Gabrielle Arnott · 2021 · Cells
Empagliflozin and Renal Sodium-Hydrogen Exchange in Healthy Subjects
Edoardo Biancalana, Chiara Rossi, Francesco Raggi, Mariarosaria Distaso, Domenico Tricò, Simona Baldi, Ele Ferrannini, Anna Solini · 2023 · The Journal of Clinical Endocrinology & Metabolism
LP ‐925219 maximizes urinary glucose excretion in mice by inhibiting both renal SGLT 1 and SGLT 2
David R. Powell, Melinda G. Smith, Deon D. Doree, Angela L. Harris, Wendy Xiong, Faika Mseeh, Alan Wilson, Suma Gopinathan, Damaris S. Diaz, Nicole C. Goodwin et al. · 2015 · Pharmacology Research & Perspectives
Euglycemic diabetic ketoacidosis: The clinical concern of SGLT2 inhibitors
Jamila Abdedaim Benmoussa, Matthew Clarke, Amulya Penmetsa, Le Yu Khine, Lina Leykina, Keith T. Diaz, Philip E. Otterbeck · 2016 · Journal of Clinical and Translational Endocrinology Case Reports
Sodium Glucose Co-transporter Inhibitors in Patients with Acromegaly and Diabetes
Adnan Zaina · 2018 · Trends in Endocrinology and Metabolism
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
Eleni Papadokostaki, Evangelos N. Liberopoulos · 2019 · Case Reports in Endocrinology
Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport
Ele Ferrannini, Ricardo Pereira Moreira, Marta Seghieri, Eleni Rebelos, Aglécio Luiz de Souza, Valéria Bahdur Chueire, Caterina Arvia, Elza Muscelli · 2020 · BMJ Open Diabetes Research & Care
Glucose uptake saturation explains glucose kinetics profiles measured by different tests
Roberto Bizzotto, Andrea Natali, Amalia Gastaldelli, Elza Muscelli, Martin Krššák, Attila Brehm, Michael Roden, Ele Ferrannini, Andrea Mari · 2016 · American Journal of Physiology-Endocrinology and Metabolism
The Clinical Spectrum of Acquired Hypomagnesemia: From Etiology to Therapeutic Approaches
Matteo Floris, Andrea Angioi, Nicola Lepori, Doloretta Piras, Gianfranca Cabiddu, Antonello Pani, Mitchell Howard Rosner · 2025 · Biomedicines
The dual role of empagliflozin: Cardio renal protection in T2DM patients
Aimen Shafiq, Eman Mahboob, Muhammad Ammar Samad, Mohammad Hassam Ur Rehman, Zoaib Habib Tharwani · 2022 · Annals of Medicine and Surgery
Emergence of a New Glucoregulatory Mechanism for Glycemic Control With Dapagliflozin/Exenatide Therapy in Type 2 Diabetes
Eugênio Cersósimo, Mariam Alatrach, Carolina Solis‐Herrera, Gozde Baskoy, John M. Adams, ANDREA A. HANSIS-DIARTE, Amalia Gastaldelli, Alberto O. Chávez, Curtis L. Triplitt, Ralph A. DeFronzo · 2023 · The Journal of Clinical Endocrinology & Metabolism
SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus
Nikola Lukic, Mirjana Mačvanin, Zoran M. Gluvic, Manfredi Rizzo, Djordje J. Radak, Jasjit S. Suri, Esma R. Isenović · 2023 · Current Medicinal Chemistry
Management of Hypertension in Diabetic Kidney Disease
Gates B. Colbert, Mohamed Essam Elrggal, Anna R. Gaddy, Hector M. Madariaga, Edgar V. Lerma · 2023 · Journal of Clinical Medicine
Re-emergence of a forgotten diabetes complication
Murat Dağdeviren, Tolga Akkan, Derun Taner Ertuğrul · 2024 · Turkish Journal of Emergency Medicine
SGLT2 inhibition improves coronary flow velocity reserve and contractility: role of glucagon signaling
Sven Göpel, Damilola D. Adingupu, Jue Wang, Elizaveta Semenova, Margareta Behrendt, Rasmus Jansson‐Löfmark, Christine Ahlström, Ann‐Cathrine Jönsson‐Rylander, V. Sashi Gopaul, RUSSELL L. ESTERLINE et al. · 2024 · Cardiovascular Diabetology
SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
Christophe E.M. De Block · 2018 · The Lancet Diabetes & Endocrinology
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add‐on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel‐design, open‐label, Phase 3 trial
Tina Vilsbøll, Ella Ekholm, EVA K. JOHNSSON, Ricardo García‐Sánchez, Nalina Dronamraju, Serge A Jabbour, Marcus Lind · 2020 · Diabetes Obesity and Metabolism
The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus
Thiquynhnga Nguyen, Min Gong, Song Wen, Xinlu Yuan, Chaoxun Wang, Jianlan Jin, Ligang Zhou · 2020 · Journal of Diabetes Research
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
Masao Koike, Hitoki Saito, Genta Kohno, Masahiro Takubo, Kentaro Watanabe, Hisamitsu Ishihara · 2021 · International Journal of Molecular Sciences
The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes
Tsuyoshi Okura, Yohei Fujioka, Risa Nakamura, Sonoko Kitao, Yuichi Ito, Mari Anno, Kazuhisa Matsumoto, Kyoko Shoji, K. Matsuzawa, Shoichiro Izawa et al. · 2022 · Scientific Reports
In Vivo Assessment of the Effects of Mono-Carrier Encapsulated Fucoxanthin Nanoparticles on Type 2 Diabetic C57 Mice and Their Oxidative Stress
Xin Zhang, Minghao Fan, Ke Luo, Wanying Xu, Jianjun Dong, Dongfeng Wang, Lu Chen, Junhong Yu · 2022 · Antioxidants
Liver autophagy-induced valine and leucine in plasma reflect the metabolic effect of sodium glucose co-transporter 2 inhibitor dapagliflozin
Futoshi Furuya, Yoshihito Fujita, Naomi Matsuo, Hiroto Minamino, Yasuo Oguri, Nozomi Isomura, Kaori Ikeda, Kohei Takesue, Ying Li, Aki Kondo et al. · 2022 · EBioMedicine
Effects of selected antidiabetics on weight loss – A retrospective database analysis
Karel Kostev, Juliana Rex, Timo Rockel, Christina Heilmaier · 2014 · Primary care diabetes
Combination therapy of sodium–glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: rationale and evidences
Awadhesh Kumar Singh, Ritu Singh · 2015 · Expert Review of Clinical Pharmacology
Sodium–glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes
Stanley S. Schwartz, Intekhab Ahmed · 2016 · Current Medical Research and Opinion
Gene expression signature: a powerful approach for drug discovery in diabetes
Smithamol Sithara, Tamsyn M. Crowley, Ken R. Walder, Kathryn Aston‐Mourney · 2016 · Journal of Endocrinology
Predictors of the response of HbA1c and body weight after SGLT2 inhibition
Takahiro Abe, Yasuhiro Matsubayashi, A. Yoshida, Hideki Suganami, Toshiaki Nojima, TAEKO OSAWA, Masahiro Ishizawa, Masahiko Yamamoto, Kazuya Fujihara, Shiro Tanaka et al. · 2017 · Diabetes & Metabolism
Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial
Ronald Goldenberg · 2017 · Clinical Therapeutics
There is a Close Association Between the Recovery of Liver Injury and Glycemic Control after SGLT2 Inhibitor Treatment in Japanese Subjects with Type 2 Diabetes: A Retrospective Clinical Study
Tomoe Kinoshita, Masashi Shimoda, Junpei Sanada, Yoshiro Fushimi, Yurie Hirata, Shintaro Irie, Atsushi Obata, Tomohiko Kimura, Hidenori Hirukawa, Kenji Kohara et al. · 2018 · Diabetes Therapy
Beyond type 2 diabetes: sodium glucose co‐transporter‐inhibition in type 1 diabetes
Torben Biester, Olga Kordonouri, Thomas Danne · 2019 · Diabetes Obesity and Metabolism
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes—cardiovascular and renal benefits in patients with chronic kidney disease
Tamara Y. Milder, SOPHIE LENA STOCKER, Dorit Samocha‐Bonet, Richard Osborne Day, Jerry Richard Greenfield · 2019 · European Journal of Clinical Pharmacology
Systematic re-evaluation of the long-used standard protocol of urease-dependent metabolome sample preparation
Jungyeon Kim, Joong Kyong Ahn, Yu Eun Cheong, Sung‐Joon Lee, Hoon‐Suk Cha, Kyoung Heon Kim · 2020 · PLoS ONE
Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences
Awadhesh Kumar Singh, Ritu Singh · 2015 · Expert Review of Clinical Pharmacology
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
Huan Ju Yu, Vincent C. Woo · 2017 · Diabetes Metabolic Syndrome and Obesity
Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen et al. · 2020 · Nutrients
Long-term effects of canagliflozin treatment on the skeleton of aged UM-HET3 mice
Gozde Yildirim, Edmara T. P. Bergamo, Sher Bahadur Poudel, Ryan Richard Ruff, Manisha Dixit, Bin Hu, Dindo Q. Mijares, Lukasz Witek, Carolyn Chlebek, David E. Harrison et al. · 2023 · GeroScience
Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
Gea Ciccarelli, Gianfranco Di Giuseppe, Francesca Cinti, Simona Moffa, Teresa Mezza, Andrea Giaccari · 2023 · Diabetes/Metabolism Research and Reviews
Beta‐cell function in type 2 diabetes ( T2DM ): Can it be preserved or enhanced?
Laure Sayyed Kassem, Aman Rajpal, Margarita Victoria Ebarle Barreiro, Faramarz Ismail‐Beigi · 2023 · Journal of Diabetes
Role of GLP-1 Receptor Agonist in Diabetic Cardio-renal Disorder: Recent Updates of Clinical and Pre-clinical Evidence
Sanket Seksaria, Bhaskar Jyoti Dutta, Mandeep Kaur, Ghanshyam Das Gupta, Surendra Haribhau Bodakhe, Amrita Singh · 2023 · Current Diabetes Reviews
Empagliflozin Normalizes Fasting Hyperglycemia and Improves Postprandial Glucose Tolerance in Totally Pancreatectomized Patients: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
Mille Baekdal, Sophie W Nielsen, Carsten Palnæs Hansen, Jan Henrik Storkholm, Gerrit van Hall, Bolette Hartmann, Jens Juul Holst, Tina Vilsbøll, Asger Lund, Filip Krag Knop · 2023 · Diabetes Care
Investigating the alterations of endocannabinoidome signaling in the human small intestine in the context of obesity and type 2 diabetes
Volatiana Rakotoarivelo, Bénédicte Allam‐Ndoul, Cyril Martin, Laurent D. Biertho, Vincenzo Di Marzo, Nicolas Flamand, Alain Veilleux · 2024 · Heliyon
Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 Diabetes
Carolina Solis‐Herrera, Yuejuan Qin, Henri Honka, Eugênio Cersósimo, Curtis L. Triplitt, Sivaram Neppala, Jemena Rajan, Francisca M. Acosta, Alexander J. Moody, Patricia Iozzo et al. · 2024 · Diabetes
Sodium-glucose cotransporter-2 inhibitors and risk of autoimmune rheumatic diseases: population based cohort study
Bin Hong, Hyesung Lee, Kyungyeon Jung, Sang Youl Rhee, Dong Keon Yon, Ju‐Young Shin · 2025 · BMJ
Sodium‐glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes
Hadi Harati, Vandhna R. Sharma, Abbas Motazedi · 2015 · Journal of Diabetes
Canagliflozin for the treatment of adults with Type 2 diabetes
Gary E. Meininger, William J. Canovatchel, David Polidori, Norm Rosenthal · 2015 · Diabetes Management
Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
Belén Dalama, Jordi Mesa · 2016 · Revista Española de Cardiología
Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes
Yoshio Nagai, Akio Ohta, Yukiyoshi Sada, Hiroyuki Kato, Yasushi Tanaka · 2016 · Expert Opinion on Pharmacotherapy
Pioglitazone prevents the increase in plasma ketone concentration associated with dapagliflozin in insulin‐treated T2DM patients: Results from the Qatar Study
Muhammad A Abdul‐Ghani, Osama Migahid, Ayman Megahed, Rajvir Singh, Mohammad Fawaz, Ralph A. DeFronzo, Amin Jayyousi · 2018 · Diabetes Obesity and Metabolism
Anti-inflammatory and atheroprotective properties of glucagon
Naoya Osaka, Hideki Kushima, Yusaku Mori, Tomomi Saito, Munenori Hiromura, Michishige Terasaki, Hironori Yashima, Makoto Ohara, Tomoyasu Fukui, Takanori Matsui et al. · 2020 · Diabetes and Vascular Disease Research
Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients
Jacek Kubica, Aldona Kubica, Klaudyna Grzelakowska, Wioleta Stolarek, Zofia Grąbczewska, Piotr Michalski, Piotr Niezgoda, Stanisław Bartuś, Andrzej Budaj, Mariusz Dąbrowski et al. · 2021 · Cardiology Journal
Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
Sarah L. Armour, Alexander Frueh, Jakob Grunnet Knudsen · 2022 · Frontiers in Pharmacology
Potential Place of SGLT2 Inhibitors in Treatment Paradigms for type 2 Diabetes Mellitus
Yehuda Handelsman · 2015 · Endocrine Practice
Short commentary on empagliflozin and its potential clinical impact
Deborah A. Hinnen · 2015 · Therapeutic Advances in Endocrinology and Metabolism
Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
Stephen N. Davis, Kashif M. Munir · 2016 · Clinical Pharmacology Advances and Applications
Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors
Umesh Kumar Dashora, Alison Gallagher, Ketan Dhatariya, Peter H. Winocour, Rob Gregory · 2016 · British Journal of Diabetes
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE‐D trial
Kim Katrine Bjerring Clemmensen, Martin Bæk Blond, Hanan Amadid, Lea Bruhn, Dorte Vistisen, Kristian Karstoft, Frederik Persson, Mathias Ried‐Larsen, Jens Juul Holst, Nicolai J. Wewer Albrechtsen et al. · 2020 · Diabetes Obesity and Metabolism
Non-glucose modulators of insulin secretion in healthy humans: (dis)similarities between islet and in vivo studies
Jean‐Claude Henquin · 2021 · Metabolism
A randomised, controlled, double blind study to assess mechanistic effects of combination therapy of dapagliflozin with exenatide QW versus dapagliflozin alone in obese patients with type 2 diabetes mellitus (RESILIENT): study protocol
Emily E. Brown, Moon Wilton, Victoria S. Sprung, Joanne Allison Harrold, Jason C. G. Halford, Andrej Stančák, Malcolm I. Burgess, Elaine Howarth, Anne Margot Umpleby, Graham John Kemp et al. · 2021 · BMJ Open
Sodium/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and water conservation
Kento Kitada, Satoshi Kidoguchi, Daisuke Nakano, Akira Nishiyama · 2021 · Journal of Pharmacological Sciences
A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat
Min Hee Lee, Ian J. Neeland, Natalia de Albuquerque Rocha, Connor Hughes, Craig R. Malloy, Eunsook S. Jin · 2021 · Metabolism Open
Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose
Mariam Alatrach, Christina Agyin, Carolina Solis‐Herrera, Olga Lavryneko, John M. Adams, Amalia Gastaldelli, Curtis L. Triplitt, Ralph Anthony DeFronzo, Eugênio Cersósimo · 2022 · Diabetes Care
New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border
Belén Dalama, Jordi Mesa · 2016 · Revista Española de Cardiología (English Edition)
Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
Alida Taberner-Cortés, Ángela Vinué, Andrea Herrero-Cervera, María Aguilar-Ballester, José Tomás Real, Deborah Jane Burks, Sergio Martínez‐Hervás, Herminia González Navarro · 2020 · International Journal of Molecular Sciences
Pathogenesis of Type 2 Diabetes Mellitus
Ralph Anthony DeFronzo · 2018 · Endocrinology
Acute Metabolic Complications of Diabetes
Philip Newland‐Jones, Mayank A Patel, Ketan Dhatariya · 2024
How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators
Pierre François Sabouret, Denis Angoulvant, Atul Pathak, M. Fysekidis, Giulia Laterra, Francesco Costa, Filippo Angelini, Pier Paolo Bocchino, Gilles Montalescot, Giuseppe Biondi‐Zoccai · 2021 · Panminerva Medica
SGLT2 inhibitors: cardiorenal metabolic drugs for the ages
Ralph Anthony DeFronzo · 2024 · Journal of Clinical Investigation
Dapagliflozin attenuates fat accumulation and insulin resistance in obese mice with polycystic ovary syndrome
Baiwei Lin, Xiaodan Guo, Wenjing Lü, Rui Lan Niu, Xiying Zeng, Zheng Chen, Caisheng Wu, Changqin Liu · 2024 · European Journal of Pharmacology
Sodium–Glucose Cotransporter 2 Inhibitors as Potential Antioxidant Therapeutic Agents in Cardiovascular and Renal Diseases
Tapan Patel, Hong Zheng, Kaushik P. Patel · 2025 · Antioxidants
Extra‐glycaemic properties of empagliflozin
Anna Solini · 2015 · Diabetes/Metabolism Research and Reviews